- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06269679
CBCT vs OPT om oral helsestatus ved 12 måneder av pasienter innlagt på sykehus for infeksiøs endokarditt. (3D STARS)
3D-avbildning (Cone Beam Computed Tomography) versus ortopantomogram på oral helsestatus ved 12 måneder av pasienter innlagt på sykehus for infeksjonsendokarditt: et multisenter randomisert overlegenhetskontrollert forsøk.
1. Infective Endocarditis (IE) is a rare and serious disease with high morbidity and mortality; 2. Streptoccoci of oral origin are the second more frequent microorganisms responsible for IE; 3. Oral Infectious Foci (OIF) are underdetected using the current recommended clinical examination/Orthopantomogram (OPT) approach; 4. Cone Beam Computed Tomography (CBCT) has a better sensitivity and sensibility to detect OIF than OPT; 5. To date, no study has been performed to assess the potential benefit of a clinical examination/CBCT approach on the oral health status in IE patients.
Thus, conducting a randomized controlled trial is highly desirable to assess the potential impact of a clinical examination/CBCT approach on the oral health status of patients hospitalized for IE and potentially to reduce IE new episodes.
Studieoversikt
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Bordeaux, Frankrike
- Rekruttering
- CHU Bordeaux - Site Pellegrin
-
Ta kontakt med:
- Elise ARRIVE
- Telefonnummer: +33/5 56 79 56 79
- E-post: elise.arrive@u-bordeaux.fr
-
Clermont-Ferrand, Frankrike
- Rekruttering
- CHU Clermont-Ferrand
-
Ta kontakt med:
- Magali VIDAL
- Telefonnummer: +33473754405
- E-post: mvidal@chu-clermontferrand.fr
-
Grenoble, Frankrike
- Rekruttering
- CHU Grenoble
-
Ta kontakt med:
- Cécile CHATEL
- Telefonnummer: +33/4 76 76 50 26
- E-post: cchatel1@chu-grenoble.fr
-
Lyon, Frankrike
- Rekruttering
- HCL
-
Ta kontakt med:
- Sarah MILLOT GUARD
- Telefonnummer: +33426680250
- E-post: sarah.millot-guard@chu-lyon.fr
-
Marseille, Frankrike
- Rekruttering
- APHM
-
Ta kontakt med:
- Jean-Hugues CATHERINE
- Telefonnummer: +33676320760
- E-post: jean-hugues.catherine@ap-hm.fr
-
Nancy, Frankrike
- Rekruttering
- CHRU Nancy
-
Ta kontakt med:
- Vanessa MOBY
- Telefonnummer: +33/3 83 39 18 00
- E-post: vanessa.moby@univ-lorraine.fr
-
Nantes, Frankrike
- Rekruttering
- CHU Nantes
-
Ta kontakt med:
- Astrid GARREAU
- E-post: astrid.garreau@chu-nantes.fr
-
Ta kontakt med:
- Alexandra CLOITRE
- Telefonnummer: +33/2.40.41.29.85
- E-post: alexandra.cloitre@univ-nantes.fr
-
Paris, Frankrike
- Rekruttering
- AP-HP - Site Bretonneau
-
Ta kontakt med:
- MESSECA Clément
- Telefonnummer: +33/1 53 11 18 00
- E-post: clement.messeca@aphp.fr
-
Toulouse, Frankrike
- Rekruttering
- CHU Toulouse
-
Ta kontakt med:
- Sarah COUSTY
- Telefonnummer: +33/5.61.32.20.30
- E-post: cousty.s@chu-toulouse.fr
-
Tours, Frankrike
- Rekruttering
- CHRU Tours
-
Ta kontakt med:
- Frédéric DENIS
- Telefonnummer: +33/2 47 47 47 47
- E-post: frederic.denis@univ-tours.fr
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Patients hospitalized or recently hospitalized for definite IE according to the 2015 ESC classification, naive patients for dental examination and imaging, whatever the IE responsible microorganism;
- Patients with a stable clinical state, meaning stabilized IE patients out of the critical phase, compatible with the performance of an OPT and a CBCT;
- Patients whose life expectancy is expected to be longer than 6 months;
- Patients who agree to visit the dental department of the hospital to carry out OIF eradication or at his/her personal dentist;
- Patients over 18 years old;
- Patients affiliated to a Social Security or a health insurance scheme;
- Patients who have given informed consent to participate to the study.
Exclusion Criteria:
- OPT or CBCT already performed before the inclusion of the patients in the study and available for the investigator during the patient's hospitalization.
- Medical contraindications to perform OPT or CBCT imaging;
- Absence of microbiologic identification of the IE responsible microorganism;
- Pregnant or breastfeeding women;
- Patients unable to give informed consent to participate to the study (under trusteeship, guardianship and legal protection).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Diagnostisk
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Ingen inngripen: OPT
Orthopantomogram = current recommended clinical examination approach (comparator procedure) |
|
|
Eksperimentell: CBCT
Cone Beam Computed Tomography = experimental clinical examination approach (procedure under evaluation) |
Cone Beam Computed Tomography (CBCT) has a better sensitivity and sensibility to detect OIF. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Superiority of CBCT
Tidsramme: Month 12
|
Number of oral infectious foci detected using orthopantomogram versus Cone Beam Computer Tomography |
Month 12
|
|
Superiority of CBCT
Tidsramme: Month 12
|
DFMT index comprising the number of decayed, filled and missing teeth |
Month 12
|
|
Superiority of CBCT
Tidsramme: Month 12
|
Number of severe periodontitis sites |
Month 12
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Diagnostic at inclusion
Tidsramme: Day 0
|
Determine the diagnostic impact of clinical examination combined with CBCT at inclusion visit (Number of OIF detected at inclusion visit through clinical examination and CBCT versus clinical examination and OPT). |
Day 0
|
|
Incident symptomatic OIF
Tidsramme: Month 12
|
Monitor incident symptomatic OIF occuring during the study impacting the initial personalized OIF management (Number of incident symptomatic OIF detected during the study). |
Month 12
|
|
Incident asymptomatic OIF
Tidsramme: Month 12
|
Monitor incident asymptomatic OIF occuring during the study i.e. OIF absent at the initial examination but identified at the ultimate visit without symptomatic episode, in patients subjected to a clinical oral examination coupled with a CBCT (Number of incident asymptomatic OIF occuring during the study i.e. OIF absent at the initial examination but detected at the ultimate visit without symptomatic episode, in patients subjected to a clinical oral examination coupled with a CBCT). |
Month 12
|
|
Oral hygiene
Tidsramme: Day 0 and Month 12
|
Evaluate the oral hygiene of the IE patients included in the study (Oral hygiene using the Oral Hygiene Index- Simplified score (OHI-S) at inclusion visit and at the end-of-study visit). |
Day 0 and Month 12
|
|
Follow-up habits
Tidsramme: Day 0 and Month 12
|
Evaluate the follow-up habits of the IE patients included in the study by number of dental visits per year at inclusion visit and at the end-of-study visit). |
Day 0 and Month 12
|
|
Follow-up habits
Tidsramme: Day 0 and Month 12
|
Evaluate the follow-up habits of the IE patients included in the study by number of dental brushings per day (specific questionnaire already validated in French version) at inclusion visit and at the end-of-study visit). |
Day 0 and Month 12
|
|
Oral health quality of life
Tidsramme: Day 0 and Month 12
|
Assess the oral health quality of life of the IE patients included in this study (Oral health quality of life using by the short version of the self-administrated Oral Health impact profile-14 questionnaire (OHIP-14), at inclusion visit and at the end-of-study visit). |
Day 0 and Month 12
|
|
Premature end of study
Tidsramme: Month 12
|
Analyse the patient's premature end of study (Causes of the patient's premature end of study: loss to follow-up, death, patient withdrawing consent). |
Month 12
|
|
Impact of dental OIF
Tidsramme: Month 12
|
Number of dental OIF detected at the end-of-study visit through clinical examination versus number of periodontal OIF detected at the inclusion visit through clinical examination. |
Month 12
|
|
Impact of periodontal OIF
Tidsramme: Month 12
|
Number of periodontal OIF detected at the end-of-study visit through clinical examination versus number of periodontal OIF detected at the inclusion visit through clinical examination. |
Month 12
|
|
Impact of mucosal OIF
Tidsramme: Month 12
|
Number of mucosal OIF detected at the end-of-study visit through clinical examination versus number of periodontal OIF detected at the inclusion visit through clinical examination. |
Month 12
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- RC23_0336
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .